Staphylococcus aureus bacteraemia (SAB) is associated with substantial morbidity and mortality. By surviving within leukocytes, S. aureus can evade both immunological defences and antimicrobial drugs, thus facilitating haematogenous dissemination. We performed a systematic review to determine whether antimicrobials with intracellular activity improve outcomes in SAB when used as an adjunct to β-lactam or glycopeptide monotherapy. The Pubmed/MEDLINE, Embase and Cochrane databases were systematically searched for eligible studies that reported on the use of first-line antimicrobials plus a single additional antimicrobial of interest in patients with SAB (any cause). Six relevant studies were identified, all reporting on rifampicin use. Four studies (three randomized controlled trials and one cohort) reported on adults with SAB, including 54 patients treated with adjunctive rifampicin and 44 standard-therapy controls. Estimated across all of these studies, adjunctive rifampicin was associated with trends towards reduced all-cause mortality and reduced clinical or bacteriological failure. The fifth study indicated that adjunctive rifampicin accelerates the resolution of persistent SAB in neonates. Data from the sixth study were considered flawed owing to differences in co-morbidities between groups. Limited data suggest that rifampicin-induced hepatitis is not clinically significant but that drug interactions are. In conclusion, adjunctive rifampicin may improve outcomes in SAB when used as an adjunct to β-lactam or glycopeptide monotherapy.
AmmerlaanH., SeifertH., HarbarthS., Brun-BuissonC., TorresA., AntonelliM., KluytmansJ., BontenM.Study on European Practices of Infections with Staphylococcus aureus (SEPIA) Study Group2009; Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis 49:997–1005 [View Article][PubMed]
Aubry-DamonH., SoussyC. J., CourvalinP.1998; Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 42:2590–2594[PubMed]
JungY. J., KohY., HongS.-B., ChungJ. W., ChoiS. H., KimN. J., KimM.-N., ChoiI. S., HanS. Y.& other authors (2010; Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 38:175–180 [View Article][PubMed]
KozielJ., Maciag-GudowskaA., MikolajczykT., BzowskaM., SturdevantD. E., WhitneyA. R., ShawL. N., DeLeoF. R., PotempaJ.2009; Phagocytosis of Staphylococcus aureus by macrophages exerts cytoprotective effects manifested by the upregulation of antiapoptotic factors. PLoS ONE 4:e5210 [View Article][PubMed]
KropecA., DaschnerF. D.1991; Penetration into tissues of various drugs active against gram-positive bacteria. J Antimicrob Chemother 27:Suppl. B9–15 [View Article][PubMed]
KubicaM., GuzikK., KozielJ., ZarebskiM., RichterW., GajkowskaB., GoldaA., Maciag-GudowskaA., BrixK.& other authors (2008; A potential new pathway for Staphylococcus aureus dissemination: the silent survival of S. aureus phagocytosed by human monocyte-derived macrophages. PLoS ONE 3:e1409 [View Article][PubMed]
LemaireS., Van BambekeF., PierardD., AppelbaumP. C., TulkensP. M.2011; Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin. Clin Infect Dis 52:Suppl. 7S493–S503 [View Article][PubMed]
LevineD. P., FrommB. S., ReddyB. R.1991; Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115:674–680 [View Article][PubMed]
MwangiM. M., WuS. W., ZhouY., SieradzkiK., de LencastreH., RichardsonP., BruceD., RubinE., MyersE.& other authors (2007; Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A 104:9451–9456 [View Article][PubMed]
NielsenS. L., ObelN., StorgaardM., AndersenP. L.1997; The effect of quinolones on the intracellular killing of Staphylococcus aureus in neutrophil granulocytes. J Antimicrob Chemother 39:617–622 [View Article][PubMed]
Public Health England2013; Voluntary Reporting of Staphylococcus aureus Bacteraemia in England, Wales and Northern Ireland, 2012; Health Protection Report (accessed 8 December 2013). http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139661325
QaziS. N., HarrisonS. E., SelfT., WilliamsP., HillP. J.2004; Real-time monitoring of intracellular Staphylococcus aureus replication. J Bacteriol 186:1065–1077 [View Article][PubMed]
RiedelD. J., WeekesE., ForrestG. N.2008; Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 52:2463–2467 [View Article][PubMed]
SakoulasG., Moise-BroderP. A., SchentagJ., ForrestA., MoelleringR. C.Jr, EliopoulosG. M.2004; Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402 [View Article][PubMed]
ThwaitesG. E., GantV.2011; Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus?. Nat Rev Microbiol 9:215–222 [View Article][PubMed]
ThwaitesG., AucklandC., BarlowG., CunninghamR., DaviesG., EdgeworthJ., GreigJ., HopkinsS., JeyaratnamD.& other authors (2012; Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial. Trials 13:241 [View Article][PubMed]
Van der AuweraP., Meunier-CarpentierF., KlasterskyJ.1983; Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections. Rev Infect Dis 5:Suppl. 3S515–S521 [View Article][PubMed]
Van der AuweraP., KlasterskyJ., ThysJ. P., Meunier-CarpentierF., LegrandJ. C.1985; Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 28:467–472 [View Article][PubMed]
VoyichJ. M., VuongC., DeWaldM., NygaardT. K., KocianovaS., GriffithS., JonesJ., IversonC., SturdevantD. E.& other authors (2009; The SaeR/S gene regulatory system is essential for innate immune evasion by Staphylococcus aureus. J Infect Dis 199:1698–1706 [View Article][PubMed]
YzermanE. P. F., BoelensH. A. M., VogelM., VerbrughH. A.1998; Efficacy and safety of teicoplanin plus rifampicin in the treatment of bacteraemic infections caused by Staphylococcus aureus.. J Antimicrob Chemother 42:233–239 [View Article][PubMed]